ArticleDiscover oncology2025
Appraising the causal role of cathepsins in genitourinary carcinoma: a two-sample mendelian randomization and prospective study based on 36,225 individuals.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting cystatin F activation enhances NK cell cytotoxicity in glioblastoma models.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCathepsin family proteases play an important role in the carcinogenesis of genitourinary carcinomas. However, the causality between serum cathepsin levels and genitourinary carcinomas remains uninvestigated.
methodsIn this study, we conducted a two-sample Mendelian Randomization (MR) analysis exploring the causal association between different types of cathepsins and genitourinary carcinomas. Univariate, bidirectional and multivariate MR analyses were conducted based on the genome-wide association studies. Moreover, linkage disequilibrium score regression (LDSC) analysis, colocalization and transcriptomic analysis were also performed. 36,225 Individual data from UK biobank was utilized for further validation.
resultsOur findings revealed seven causal associations following univariate analysis, in which five correlations were further validated in multivariate analysis. Cathepsin S (CTSS) was positively associated with papillary renal cell carcinoma (pRCC) [IVW: OR (95%CI) 1.444 (1.103-1.890), p: 8*10-3], and LDSC analysis indicated a genetic correlation between CTSS and pRCC [rg (SE): 0.559 (0.225); p: 0.013]. Other causal correlations included cathepsin B (CTSB), positively associated with testicular non-seminoma, and cathepsin L2 (CTSL2/CTSV), negatively associated with overall kidney cancer and pRCC. Transcriptomic analysis further validated the findings from MR analysis. In the UK biobank, CTSL2 was found to be negatively associated with the risk of cancer of the kidney [HR (95%CI) 0.567 (0.368, 0.873), p: 0.01].
conclusionsCathepsins played an important role in urogenital carcinogenesis. Further large-scale studies are warranted for extended validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.